Drawings



FIG. 1



Anti-ZZS01, malignant melanoma anti-ZZS05, esophageal cancer anti-ZZS05, T-cell lymphoma

FIG. 2

A.





Nasopharyngeal Cancer Malignant Melanoma

ID6 IHC Representative Results

B.





Lung adenocarcinoma gastric cancer

F11 IHC Representative Results

FIG. 3


A
Control
F11
B
Body weight (g)
days
Control
F11
C
Tumor volume (mm3)
days
Control
F11
**

FIG. 4


A
Control
F11
B
Body weight (g)
days
Control
F11
C
Tumor volume (mm3)
days
Control
F11
**

FIG. 5

A


**
*
*
ns
**
**
15
10
5
Apoptosis (%)
O
O+NK+PBS
O+NK+IgG
O+NK+A-1P13-0.1
O+NK+A-1P13-1
O+NK+A-1P13-10

B


*
*
***
ns
ns
ns
20
15
10
5
0
Apoptosis (%)
O
O+NK+PBS
O+NK+LgG1
O+NK+A-1P13-0.1
O+NK+A-1P13-1
O+NK+A-1P13-10

FIG. 6


organoid+NK+tumor-independent antibody
organoid+NK+candidate antibody
organoid+NK
organoid+PBS
GC
HCC
LC
PADC
organoid+NK+tumor-independent antibody
organoid+NK+candidate antibody
organoid+NK
organoid+PBS
AOC
BC
CRC
EC

FIG.7


Viability(%)
100
50
0
NK
candidate antibody
tumor-independent antibody
PBS
EC
CRC
BC
GC
AOC
PADC
HCC
LC

FIG.8